Simvastatin has deleterious effects on human first trimester placental explants | Zendy

Irina Kenis | Zendy; Shelly TartakoverMatalon | Zendy; N. Cherepnin | Zendy; Liat Drucker | Zendy; Ami Fishman | Zendy; Meir Pomeranz | Zendy; Michael Lishner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Simvastatin has deleterious effects on human first trimester placental explants

Author(s) -

Irina Kenis,

Shelly TartakoverMatalon,

N. Cherepnin,

Liat Drucker,

Ami Fishman,

Meir Pomeranz,

Michael Lishner

Publication year - 2005

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/dei120

Subject(s) - simvastatin , trophoblast , cytotrophoblast , matrigel , endocrinology , medicine , placenta , andrology , hmg coa reductase , reductase , biology , pregnancy , fetus , enzyme , biochemistry , genetics , angiogenesis

Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA reductase), the rate-limiting enzyme of the mevalonate pathway, and have been used successfully in the treatment of hypercholesterolaemia. Animal models have provided evidence for the teratogenic effects of statins on pregnancy outcome. Thus statins are contraindicated during pregnancy. However, conflicting data are available from inadvertent use of statins in human pregnancy. Therefore we decided to explore the effects of simvastatin on the placenta in an in vitro human placental model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research